NASDAQ | TSX: ACB
Canada's
Leading Medical Cannabis Company and MedReleaf Australia Launch New
Oil
Products for Enhanced Patient Care Options
EDMONTON, AB, Oct. 16,
2024 /CNW/ - Aurora Cannabis Inc.,
(NASDAQ: ACB) (TSX: ACB) – the Canadian based global leader in
medical cannabis, in conjunction with MedReleaf Australia, is
pleased to announce an enhanced product range of premium medical
cannabis oil in Australia. This
expansion reinforces Aurora's dedication to providing high-quality,
innovative cannabis solutions to patients around the world. Now
available for physicians to prescribe, the new cannabis oils
include a variety of cannabinoid ratios to suit diverse patient
needs.
The newly launched cannabis oil products include Aurora THC 25
(Sativa) in a 30mL bottle, Aurora THC 25 (Indica) in a 30mL bottle,
Aurora 12.5:12.5 oil in a 30mL bottle, Aurora 50:50 oil in a 30mL
bottle, and Aurora 10:100 oil in a 30mL bottle. Each formulation
offers varying cannabinoid ratios to support personalized treatment
options for patients.
"We are thrilled to bring this enhanced range of cannabis oil
products to the Australian market," said Andre Jerome, Executive Vice President, Global
Business Development at Aurora. "Our mission is to offer healthcare
providers and their patients a broader selection of treatment
options that meet their various medical needs. By expanding our
product portfolio, we continue to demonstrate our commitment to
advancing patient care through high-quality, science-driven
cannabis solutions."
The newly available oils are developed and manufactured at
Aurora's Canadian TGA and EU GMP certified facility, add to the
expanding lineup with increased cannabinoid variety. The new
products allow Doctors to tailor treatments more precisely,
enhancing patient care. These offerings are another step forward in
MedReleaf Australia's mission to expand access to quality medical
cannabis options for patients across the country.
Key features of Aurora's new cannabis oil products
include:
- Comprehensive Cannabinoid Profiles: Designed to provide
targeted and effective relief with a variety of THC and CBD
ratios.
- High Standards of Quality and Safety: Manufactured in
TGA-GMP certified facilities, adhering to rigorous quality control
measures.
- Broad Selection: Wide range of unique oil
formulations, allowing for customized patient care.
For additional information, healthcare professionals are
encouraged to contact MedReleaf Australia's clinical support team
or visit their website: www.medreleafaustralia.com.au.
About Aurora Cannabis
Aurora is opening the world to cannabis, serving both the
medical and consumer markets across Canada, Europe, Australia and South
America. Headquartered in Edmonton, Alberta, Aurora is a pioneer in
global cannabis, dedicated to helping people improve their lives.
The Company's adult- use brand portfolio includes Aurora Drift, San
Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical
cannabis brands include MedReleaf, CanniMed, Aurora and Whistler
Medical Marijuana Co, as well as international brands, Pedanios,
Bidiol, IndiMed and CraftPlant. Aurora also has a controlling
interest in Bevo Farms Ltd., North
America's leading supplier of propagated agricultural
plants. Driven by science and innovation, and with a focus on
high-quality cannabis products, Aurora's brands continue to break
through as industry leaders in the medical, wellness and adult
recreational markets wherever they are launched. Learn more at
www.auroramj.com and follow us on X and LinkedIn.
Aurora's Common Shares trade on the NASDAQ and TSX under the symbol
"ACB".
About MedReleaf Australia
MedReleaf Australia is a subsidiary of Aurora Cannabis Inc.,
established in 2016. MedReleaf is licensed by the Australian
Federal Government's Office of Drug Control (ODC) to cultivate and
manufacture medical cannabis. MedReleaf also has licenses to
import, export and wholesale medical cannabis. Its wholly owned
subsidiary in New Zealand also has
a Medicinal Cannabis Supply Licence issued by the New Zealand
Ministry of Health. MedReleaf Australia is backed by more than 50
combined years of pharmaceutical and healthcare expertise, is
driven by Research and Development. An asset-lean distinct business
positioned to take advantage of a rapidly growing market, built to
service the Australian and New
Zealand medical industries including doctors, pharmacists,
and patients.
Forward Looking Information
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements").
Forward-looking statements are frequently characterized by words
such as "plan", "continue", "expect", "project", "intend",
"believe", "anticipate", "estimate", "may", "will", "potential",
"proposed" and other similar words, or statements that certain
events or conditions "may" or "will" occur. Forward-looking
statements made in this news release include, but are not limited
to, statements regarding the expansion of the Company's product
portfolio in the Australian market and associated benefits, and the
Company's continued commitment to advancing patient care and
expanding access to medical cannabis globally.
These forward-looking statements are only predictions. Forward
looking information or statements contained in this news release
have been developed based on assumptions management considers to be
reasonable. Material factors or assumptions involved in developing
forward-looking statements include, without limitation, publicly
available information from governmental sources as well as from
market research and industry analysis and on assumptions based on
data and knowledge of this industry which the Company believes to
be reasonable. Forward-looking statements are subject to a variety
of risks, uncertainties and other factors that management believes
to be relevant and reasonable in the circumstances could cause
actual events, results, level of activity, performance, prospects,
opportunities or achievements to differ materially from those
projected in the forward-looking statements. These risks include,
but are not limited to, the ability to retain key personnel, the
ability to continue investing in infrastructure to support growth,
the ability to obtain financing on acceptable terms, the continued
quality of our products, customer experience and retention, the
development of third party government and non-government consumer
sales channels, management's estimates of consumer demand in
Canada and in jurisdictions where
the Company exports, expectations of future results and expenses,
the risk of successful integration of acquired business and
operations (with respect to the Transaction and more generally with
respect to future acquisitions), management's estimation that
SG&A will grow only in proportion of revenue growth, the
ability to expand and maintain distribution capabilities, the
impact of competition, the general impact of financial market
conditions, the yield from cannabis growing operations, product
demand, changes in prices of required commodities, competition, and
the possibility for changes in laws, rules, and regulations in the
industry, epidemics, pandemics or other public health crises and
other risks, uncertainties and factors set out under the heading
"Risk Factors" in the Company's annual information from dated
June 20, 2024 (the "AIF") and filed
with Canadian securities regulators available on the Company's
issuer profile on SEDAR+ at www.sedarplus.com and filed with
and available on the SEC's website at www.sec.gov. The Company
cautions that the list of risks, uncertainties and other factors
described in the AIF is not exhaustive and other factors could also
adversely affect its results. Readers are urged to consider the
risks, uncertainties and assumptions carefully in evaluating the
forward-looking statements and are cautioned not to place undue
reliance on such information. The Company is under no obligation,
and expressly disclaims any intention or obligation, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as expressly
required by applicable securities law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aurora-introduces-innovative-cannabis-oil-range-to-meet-diverse-patient-needs-in-australia-302277181.html
SOURCE Aurora Cannabis Inc.
